{"id":46627,"date":"2022-07-27T14:02:11","date_gmt":"2022-07-27T12:02:11","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/alnylam-uncovers-genetic-mutations-in-inhbe-that-protect-against-abdominal-obesity\/"},"modified":"2022-07-27T14:02:11","modified_gmt":"2022-07-27T12:02:11","slug":"alnylam-uncovers-genetic-mutations-in-inhbe-that-protect-against-abdominal-obesity","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/alnylam-uncovers-genetic-mutations-in-inhbe-that-protect-against-abdominal-obesity\/","title":{"rendered":"Alnylam Uncovers Genetic Mutations in INHBE That Protect Against Abdominal Obesity"},"content":{"rendered":"
\n

\n– Publication in Nature Communications Reports that People with Loss of Function Mutations in the INHBE Gene Have Reduced Abdominal Fat, a Favorable Metabolic Profile, and are at Lower Risk of Cardiovascular Disease and Type 2 Diabetes –<\/i>\n<\/p>\n

\n– Alnylam to Pursue INHBE as a Therapeutic Target for Cardiometabolic Disease –<\/i>\n<\/p>\n

CAMBRIDGE, Mass.–(BUSINESS WIRE)–Alnylam Pharmaceuticals, Inc.<\/a> (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that the Company and collaborators have identified mutations in the INHBE<\/i> gene associated with protection against abdominal obesity and metabolic syndrome \u2013 a condition impacting more than 20 percent of adults worldwide. The discovery leveraged sequencing data from more than 360,000 individuals in UK Biobank, and was published in the 13th<\/sup> issue of Nature Communications<\/a><\/i>. The published data show that rare mutations in the liver-expressed INHBE<\/i> gene are associated with lower waist-to-hip ratio adjusted for body mass index (WHRadjBMI), a surrogate for abdominal fat that is causally linked to type 2 diabetes and coronary heart disease. Findings support the potential of INHBE <\/i>to be evaluated <\/i>as a novel therapeutic target for the treatment of cardiometabolic disease. The Company plans to pursue a development candidate for INHBE<\/i> and its gene product, Activin E, leveraging its liver IKARIA\u2122 platform.\n<\/p>\n

<\/a><\/p>\n

\n\u201cWe are thrilled that our investment in genetic databases like UK Biobank is proving to be fruitful in identifying novel targets in highly prevalent diseases with continued unmet need,\u201d said Paul Nioi, Ph.D., Vice President, Discovery and Translational Research, and the Leader of Alnylam\u2019s Human Genetics Group. \u201cThere is a well-established causal link between increased waist-to-hip ratio and a person\u2019s risk of cardiometabolic conditions. By exploring the genetic determinants of waist-to-hip ratio in this study, important insights into the mechanisms that contribute to body fat distribution were uncovered helping identify potential therapeutic targets for abdominal obesity, like INHBE<\/i>. The results of this exome-wide analysis suggest that targeting INHBE<\/i> is predicted to have broad beneficial effects on all facets of metabolic syndrome with potential reductions in the risk of type 2 diabetes and coronary heart disease. We are currently testing this hypothesis, with the goal of pursuing a development candidate targeting INHBE<\/i> in the near future.\u201d\n<\/p>\n

\n\u201cWe are delighted to see that the uniquely detailed data within UK Biobank – generously donated by our half a million participants – is accelerating research into important health conditions. Thanks to the collaboration with leading life sciences companies in the UK Biobank Exome Sequencing Consortium, the UK Biobank resource is helping to rapidly identify new therapeutic targets for abdominal obesity,\u201d said Professor Naomi Allen, UK Biobank Chief Scientist.\n<\/p>\n

\nUsing whole exome-sequencing data from UK Biobank, Alnylam and collaborators mined for gene variants associated with lower WHRadjBMI in more than 360,000 individuals of European ancestry, revealing \u201closs of function\u201d in INHBE<\/i> as a novel genetic factor contributing to a healthier fat distribution. Rare predicted loss of function (pLOF) variants in INHBE<\/i>, were carried by one in 587 individuals and were associated with lower abdominal fat. In vitro<\/i> characterization of the most common INHBE<\/i> pLOF variant in the study, indicated an approximately 90% reduction in secreted activin E levels. Further analysis of INHBE<\/i> pLOF carriers revealed a favorable metabolic profile, including decreased triglycerides, increased high-density lipoprotein cholesterol, and decreased fasting glucose. There were no associations suggesting adverse effects of INHBE<\/i> pLOF, and carriers of these variants did not show evidence of excess mortality. The study also detected associations with lower WHRadjBMI for variants in ACVR1C<\/i>, encoding an activin receptor, further highlighting the involvement of activins in regulating fat distribution.\n<\/p>\n

\nAbout UK Biobank<\/b>\n<\/p>\n

\nUK Biobank is a large-scale biomedical database and research resource, containing in-depth genetic and health information from half a million UK participants. The database, which is regularly augmented with additional data, is globally accessible to approved researchers and scientists undertaking vital research into the most common and life-threatening diseases. UK Biobank\u2019s research resource is a major contributor to the advancement of modern medicine and treatment and has enabled several scientific discoveries that improve human health.\n<\/p>\n

\nThe UK Biobank Exome Sequencing Consortium (UKB-ESC)<\/b>\n<\/p>\n

\nIn 2018, Alnylam and partners Regeneron, AbbVie, AstraZeneca, Biogen, and Pfizer announced an agreement with UK Biobank to form the UK Biobank Exome Sequencing Consortium (UKB-ESC), a pre-competitive consortium that aims to sequence the whole exomes of 500,000 volunteer participants in the biomedical resource. The goal of the consortium, which represents the largest ever effort to use genome sequencing to map the DNA of a group of people, is to uncover insights that allow researchers to pinpoint new drug targets at the core of human disease in order to develop effective treatments for patients. To date, the UKB-ESC has made whole-exome sequencing data from 450,000 participants available to the global health community for research purposes and will continue to make all sequenced data available at no cost under the terms of the UKB-ESC charter and the founding principles of UK Biobank.\n<\/p>\n

\nAbout Cardiometabolic Disease<\/b>\n<\/p>\n

\nCardiometabolic diseases are the number one cause of death in the world; these include but are not limited to cardiovascular disease, obesity, diabetes mellitus, and non-alcoholic fatty liver disease. An estimated 47 million people in the U.S. alone are living with some form of cardiometabolic disease. Despite the availability of many well-established treatments for cardiometabolic diseases, the substantial mortality associated with this group of diseases underscores the high unmet medical need for new therapeutic options, including those directed to novel disease-modifying targets, and with potential to address poor medication adherence.\n<\/p>\n

\nAbout IKARIA\u2122 Platform<\/b>\n<\/p>\n

\nAlnylam\u2019s IKARIA platform takes advantage of more than two decades of experience in developing RNAi therapeutics. IKARIA enables an extended duration of activity in preclinical studies, with potential for annual dosing in humans, and has design features which provide exquisite specificity, further widening the potential therapeutic index, with enhanced target reduction levels.\n<\/p>\n

\nAbout RNAi<\/b>\n<\/p>\n

\nRNAi (RNA interference) is a natural cellular process of gene silencing that represents one of the most promising and rapidly advancing frontiers in biology and drug development today. Its discovery has been heralded as “a major scientific breakthrough that happens once every decade or so,” and was recognized with the award of the 2006 Nobel Prize for Physiology or Medicine. By harnessing the natural biological process of RNAi occurring in our cells, a new class of medicines, known as RNAi therapeutics, is now a reality. Small interfering RNA (siRNA), the molecules that mediate RNAi and comprise Alnylam’s RNAi therapeutic platform, function upstream of today\u2019s medicines by potently silencing messenger RNA (mRNA) \u2013 the genetic precursors \u2013 that encode for disease-causing or disease pathway proteins, thus preventing them from being made. This is a revolutionary approach with the potential to transform the care of patients with genetic and other diseases.\n<\/p>\n

\nAbout Alnylam Pharmaceuticals<\/b>\n<\/p>\n

\nAlnylam (Nasdaq: ALNY) has led the translation of RNA interference (RNAi) into a whole new class of innovative medicines with the potential to transform the lives of people afflicted with rare and prevalent diseases with unmet need. Based on Nobel Prize-winning science, RNAi therapeutics represent a powerful, clinically validated approach yielding transformative medicines. Since its founding 20 years ago, Alnylam has led the RNAi Revolution<\/i> and continues to deliver on a bold vision to turn scientific possibility into reality. Alnylam\u2019s commercial RNAi therapeutic products are ONPATTRO\u00ae<\/sup> (patisiran), GIVLAARI\u00ae<\/sup> (givosiran), OXLUMO\u00ae<\/sup> (lumasiran), AMVUTTRA\u2122 (vutrisiran), and Leqvio\u00ae<\/sup> (inclisiran) being developed and commercialized by Alnylam\u2019s partner, Novartis. Alnylam has a deep pipeline of investigational medicines, including six product candidates that are in late-stage development. Alnylam is executing on its \u201cAlnylam P5<\/sup>x25<\/i>\u201d strategy to deliver transformative medicines in both rare and common diseases benefiting patients around the world through sustainable innovation and exceptional financial performance, resulting in a leading biotech profile. Alnylam is headquartered in Cambridge, MA. For more information about our people, science and pipeline, please visit www.alnylam.com<\/a> and engage with us on Twitter at @Alnylam<\/a>, on LinkedIn<\/a>, or on Instagram<\/a>.\n<\/p>\n

\nAlnylam Forward Looking Statements<\/b>\n<\/p>\n

\nVarious statements in this release concerning Alnylam’s future expectations, plans and prospects, including, without limitation, Alnylam\u2019s views with respect to pursuing INHBE<\/i> as a therapeutic target for cardiometabolic disease and its goal to identify a development candidate targeting INHBE<\/i> in the near future, Alnylam\u2019s aspiration to become a leading biotech company, and the planned achievement of its \u201cAlnylam P5<\/sup>x25\u201d<\/i> strategy, constitute forward-looking statements for the purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995. Actual results and future plans may differ materially from those indicated by these forward-looking statements as a result of various important risks, uncertainties and other factors, including, without limitation: the direct or indirect impact of the COVID-19 global pandemic or any future pandemic on Alnylam\u2019s business, results of operations and financial condition and the effectiveness or timeliness of Alnylam\u2019s efforts to mitigate the impact of the pandemic; the potential impact of the recent leadership transition on Alnylam\u2019s ability to attract and retain talent and to successfully execute on its \u201cAlnylam P5<\/sup>x25\u201d<\/i> strategy; Alnylam’s ability to discover and develop novel drug candidates, including a development candidate targeting INHBE<\/i>, and delivery approaches, and successfully demonstrate the efficacy and safety of its product candidates; the pre-clinical and clinical results for its product candidates; actions or advice of regulatory agencies and Alnylam\u2019s ability to obtain and maintain regulatory approval for its product candidates, as well as favorable pricing and reimbursement; successfully launching, marketing and selling its approved products globally; delays, interruptions or failures in the manufacture and supply of its product candidates or its marketed products; obtaining, maintaining and protecting intellectual property; Alnylam\u2019s ability to successfully expand the indication for OXLUMO, ONPATTRO and AMVUTTRA in the future; Alnylam’s ability to manage its growth and operating expenses through disciplined investment in operations and its ability to achieve a self-sustainable financial profile in the future without the need for future equity financing; Alnylam\u2019s ability to maintain strategic business collaborations; Alnylam’s dependence on third parties for the development and commercialization of certain products, including Novartis, Sanofi, Regeneron and Vir; the outcome of litigation; the potential impact of current and the risk of future government investigations; and unexpected expenditures; as well as those risks more fully discussed in the \u201cRisk Factors\u201d filed with Alnylam’s most recent Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission (SEC) and in its other SEC filings. In addition, any forward-looking statements represent Alnylam’s views only as of today and should not be relied upon as representing its views as of any subsequent date. Alnylam explicitly disclaims any obligation, except to the extent required by law, to update any forward-looking statements.\n<\/p>\n

Contacts<\/b> <\/p>\n

\nAlnylam Pharmaceuticals, Inc.<\/b><\/p>\n

Christine Regan Lindenboom
\n
(Investors and Media)
\n
+1-617-682-4340<\/p>\n

Josh Brodsky
\n
(Investors)
\n
+1-617-551-8276\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

– Publication in Nature Communications Reports that People with Loss of Function Mutations in the INHBE Gene Have Reduced Abdominal Fat, a Favorable Metabolic Profile, and are at Lower Risk of Cardiovascular Disease and Type 2 Diabetes – – Alnylam to Pursue INHBE as a Therapeutic Target for Cardiometabolic Disease – CAMBRIDGE, Mass.–(BUSINESS WIRE)–Alnylam Pharmaceuticals, … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-46627","6":"format-standard","7":"category-industry"},"yoast_head":"\nAlnylam Uncovers Genetic Mutations in INHBE That Protect Against Abdominal Obesity - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/alnylam-uncovers-genetic-mutations-in-inhbe-that-protect-against-abdominal-obesity\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Alnylam Uncovers Genetic Mutations in INHBE That Protect Against Abdominal Obesity - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"– Publication in Nature Communications Reports that People with Loss of Function Mutations in the INHBE Gene Have Reduced Abdominal Fat, a Favorable Metabolic Profile, and are at Lower Risk of Cardiovascular Disease and Type 2 Diabetes – – Alnylam to Pursue INHBE as a Therapeutic Target for Cardiometabolic Disease – CAMBRIDGE, Mass.–(BUSINESS WIRE)–Alnylam Pharmaceuticals, ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/alnylam-uncovers-genetic-mutations-in-inhbe-that-protect-against-abdominal-obesity\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2022-07-27T12:02:11+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20220726005945\/en\/1161817\/21\/Alnylam_Corporate_Logo.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"9 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/alnylam-uncovers-genetic-mutations-in-inhbe-that-protect-against-abdominal-obesity\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/alnylam-uncovers-genetic-mutations-in-inhbe-that-protect-against-abdominal-obesity\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Alnylam Uncovers Genetic Mutations in INHBE That Protect Against Abdominal Obesity\",\"datePublished\":\"2022-07-27T12:02:11+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/alnylam-uncovers-genetic-mutations-in-inhbe-that-protect-against-abdominal-obesity\\\/\"},\"wordCount\":1791,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/alnylam-uncovers-genetic-mutations-in-inhbe-that-protect-against-abdominal-obesity\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220726005945\\\/en\\\/1161817\\\/21\\\/Alnylam_Corporate_Logo.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/alnylam-uncovers-genetic-mutations-in-inhbe-that-protect-against-abdominal-obesity\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/alnylam-uncovers-genetic-mutations-in-inhbe-that-protect-against-abdominal-obesity\\\/\",\"name\":\"Alnylam Uncovers Genetic Mutations in INHBE That Protect Against Abdominal Obesity - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/alnylam-uncovers-genetic-mutations-in-inhbe-that-protect-against-abdominal-obesity\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/alnylam-uncovers-genetic-mutations-in-inhbe-that-protect-against-abdominal-obesity\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220726005945\\\/en\\\/1161817\\\/21\\\/Alnylam_Corporate_Logo.jpg\",\"datePublished\":\"2022-07-27T12:02:11+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/alnylam-uncovers-genetic-mutations-in-inhbe-that-protect-against-abdominal-obesity\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/alnylam-uncovers-genetic-mutations-in-inhbe-that-protect-against-abdominal-obesity\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/alnylam-uncovers-genetic-mutations-in-inhbe-that-protect-against-abdominal-obesity\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220726005945\\\/en\\\/1161817\\\/21\\\/Alnylam_Corporate_Logo.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220726005945\\\/en\\\/1161817\\\/21\\\/Alnylam_Corporate_Logo.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/alnylam-uncovers-genetic-mutations-in-inhbe-that-protect-against-abdominal-obesity\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Alnylam Uncovers Genetic Mutations in INHBE That Protect Against Abdominal Obesity\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Alnylam Uncovers Genetic Mutations in INHBE That Protect Against Abdominal Obesity - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/alnylam-uncovers-genetic-mutations-in-inhbe-that-protect-against-abdominal-obesity\/","og_locale":"en_US","og_type":"article","og_title":"Alnylam Uncovers Genetic Mutations in INHBE That Protect Against Abdominal Obesity - Pharma Trend","og_description":"– Publication in Nature Communications Reports that People with Loss of Function Mutations in the INHBE Gene Have Reduced Abdominal Fat, a Favorable Metabolic Profile, and are at Lower Risk of Cardiovascular Disease and Type 2 Diabetes – – Alnylam to Pursue INHBE as a Therapeutic Target for Cardiometabolic Disease – CAMBRIDGE, Mass.–(BUSINESS WIRE)–Alnylam Pharmaceuticals, ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/alnylam-uncovers-genetic-mutations-in-inhbe-that-protect-against-abdominal-obesity\/","og_site_name":"Pharma Trend","article_published_time":"2022-07-27T12:02:11+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20220726005945\/en\/1161817\/21\/Alnylam_Corporate_Logo.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"9 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/alnylam-uncovers-genetic-mutations-in-inhbe-that-protect-against-abdominal-obesity\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/alnylam-uncovers-genetic-mutations-in-inhbe-that-protect-against-abdominal-obesity\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Alnylam Uncovers Genetic Mutations in INHBE That Protect Against Abdominal Obesity","datePublished":"2022-07-27T12:02:11+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/alnylam-uncovers-genetic-mutations-in-inhbe-that-protect-against-abdominal-obesity\/"},"wordCount":1791,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/alnylam-uncovers-genetic-mutations-in-inhbe-that-protect-against-abdominal-obesity\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20220726005945\/en\/1161817\/21\/Alnylam_Corporate_Logo.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/alnylam-uncovers-genetic-mutations-in-inhbe-that-protect-against-abdominal-obesity\/","url":"https:\/\/pharma-trend.com\/en\/alnylam-uncovers-genetic-mutations-in-inhbe-that-protect-against-abdominal-obesity\/","name":"Alnylam Uncovers Genetic Mutations in INHBE That Protect Against Abdominal Obesity - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/alnylam-uncovers-genetic-mutations-in-inhbe-that-protect-against-abdominal-obesity\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/alnylam-uncovers-genetic-mutations-in-inhbe-that-protect-against-abdominal-obesity\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20220726005945\/en\/1161817\/21\/Alnylam_Corporate_Logo.jpg","datePublished":"2022-07-27T12:02:11+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/alnylam-uncovers-genetic-mutations-in-inhbe-that-protect-against-abdominal-obesity\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/alnylam-uncovers-genetic-mutations-in-inhbe-that-protect-against-abdominal-obesity\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/alnylam-uncovers-genetic-mutations-in-inhbe-that-protect-against-abdominal-obesity\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20220726005945\/en\/1161817\/21\/Alnylam_Corporate_Logo.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20220726005945\/en\/1161817\/21\/Alnylam_Corporate_Logo.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/alnylam-uncovers-genetic-mutations-in-inhbe-that-protect-against-abdominal-obesity\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Alnylam Uncovers Genetic Mutations in INHBE That Protect Against Abdominal Obesity"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/46627","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=46627"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/46627\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=46627"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=46627"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=46627"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}